Peer-reviewed veterinary case report
Antiviral drug PMPDAP tested in cats with feline immunodeficiency
By Hartmann, Anja D et al.·Published in Journal of feline medicine and surgery·2012·Clinic for Small Animal Medicine, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical efficacy of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) in the treatment of feline immunodeficiency virus-infected cats.
- Species:
- cat
Plain-English summary
Twenty cats with feline immunodeficiency virus (FIV) were treated with a new medication called PMPDAP to see if it could help improve their health. They received this treatment twice a week for six weeks, while another group received a placebo. Although there were no major differences in health outcomes between the two groups, some cats on PMPDAP showed slight improvements in their overall health scores. However, there were also some side effects noted in the cats receiving PMPDAP. This treatment might be a potential option for FIV-infected cats in the future, but veterinarians will need to keep an eye on any side effects.
People also search for: cat FIV treatment options · feline immunodeficiency virus symptoms · PMPDAP side effects in cats
Abstract
In in vitro studies, the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) inhibited the replication of feline immunodeficiency virus (FIV). No information about its clinical efficacy is available so far. The aim of this prospective placebo-controlled, double-blinded study was to evaluate the antiviral efficacy of PMPDAP in cats naturally infected with FIV. Twenty cats were randomly assigned to two treatment groups receiving either PMPDAP (25 mg/kg) or placebo twice per week subcutaneously for 6 weeks. The general health status (Karnofsky's score), clinical signs, laboratory, immunological, and surrogate parameters were evaluated. No significant differences were found between PMPDAP- and placebo-treated cats, although cats treated with PMPDAP showed a tendency for improvement in their Karnofsky's score and clinical signs. Haematological side effects were noted in the PMPDAP-treated cats. Thus, PMPDAP may be an option in treating cats if it becomes available for veterinarians, but side effects have been monitored.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22314085/